Oncological treatment software developer Ziliomics has raised an undisclosed sum from Fight Against Cancer Innovation Trust, a commercialisation partner of OICR.
Ziliomics, a Canada-based oncological treatment software spinout of commercialisation unit Fight Against Cancer Innovation Trust (Facit), obtained an undisclosed amount of seed financing yesterday from Facit’s Prospects Oncology Fund.
Facit is the commercialisation partner of the Ontario Institute for Cancer Research (OICR), whose informatics and genomics experts came up with the idea behind Ziliomics.
Prospects Oncology Fund launched in March 2017 to drive Ontario-based oncological projects through the proof-of-concept stage towards further investment.
Ziliomics is developing biomedical data analytics software that relies on artificial intelligence to provide insights for oncologists. Its lead product is a modular genomic processing tool, Heliotrope, that interprets large quantities of sequencing data that can be verified manually.
Heliotrope has already been trialled in a clinical genomics setting and Ziliomics will use some of the proceeds for continued development. Funds will also help position the spinout as it looks to secure corporate partnerships and additional financing.
David O’Neill, who became the permanent president of Facit earlier this month, said: “Since the human genome project, OICR has been a central player in the genomics revolution of healthcare and a well-respected leader in cancer research.
“Our investment leverages years of evolving expertise that culminated in this exciting genomics intelligence tool called Heliotrope.”
